These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 21426055)

  • 1. Interview with Jürg Zimmermann, global head of oncology & exploratory chemistry at Novartis.
    Zimmermann J
    Future Med Chem; 2009 Nov; 1(8):1395-8. PubMed ID: 21426055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. STI571 revolution: can the newer targeted drugs measure up?
    Garber K
    J Natl Cancer Inst; 2001 Jul; 93(13):970-3. PubMed ID: 11438556
    [No Abstract]   [Full Text] [Related]  

  • 3. 21st-century oncology: a tangled web.
    Keating P; Cambrosio A
    Lancet; 2013 Dec; 382(9909):e45-6. PubMed ID: 24350356
    [No Abstract]   [Full Text] [Related]  

  • 4. Glivec and beyond.
    Eur J Cancer; 2006 Aug; 42(12):1695. PubMed ID: 16998957
    [No Abstract]   [Full Text] [Related]  

  • 5. a suitable case for treatment. The National Institute for Clinical Excellence's change of heart over cancer drug Glivec has been applauded by clinicians--and patients.
    Siddall R
    Health Serv J; 2002 Aug; 112(5819):10. PubMed ID: 12356018
    [No Abstract]   [Full Text] [Related]  

  • 6. [A rare complication of imatinib mesylate therapy: drug-induced pneumonitis].
    Stakhina OV; Turkina AG; Kostina IE; Kochkareva IuB
    Ter Arkh; 2010; 82(2):59-61. PubMed ID: 20387680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Origin of resistance to Imatinib mesylate: lessons learned from this experience].
    Roche-Lestienne C; Mahon FX; Preudhomme C
    Med Sci (Paris); 2004 Dec; 20(12):1125-30. PubMed ID: 15581468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. David A. Karnofsky Award lecture. Imatinib as a paradigm of targeted therapies.
    Druker BJ
    J Clin Oncol; 2003 Dec; 21(23 Suppl):239s-245s. PubMed ID: 14645403
    [No Abstract]   [Full Text] [Related]  

  • 9. Imatinib mesylate.
    Al-Hadiya BM; Bakheit AH; Abd-Elgalil AA
    Profiles Drug Subst Excip Relat Methodol; 2014; 39():265-97. PubMed ID: 24794909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Targeted treatment of cancers with imatinib mesylate (STI571, Gleevec): results of Asco 2002].
    Ray-Coquard I; Blay JY
    Bull Cancer; 2002 Jun; 89(6):567-9. PubMed ID: 12135855
    [No Abstract]   [Full Text] [Related]  

  • 11. Imatinib mesylate (Glivec, Gleevec) in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST).
    Hochhaus A
    Ann Hematol; 2004; 83 Suppl 1():S65-6. PubMed ID: 15124676
    [No Abstract]   [Full Text] [Related]  

  • 12. Genzyme launches diagnostic to monitor Gleevec resistance.
    Pharmacogenomics; 2006 Apr; 7(3):267. PubMed ID: 16610938
    [No Abstract]   [Full Text] [Related]  

  • 13. Imatinib for chronic myeloid leukaemia: a NICE mess.
    Barbour V
    Lancet; 2001 Nov; 358(9292):1478. PubMed ID: 11705557
    [No Abstract]   [Full Text] [Related]  

  • 14. Spotlight on imatinib mesylate in chronic myeloid leukemia.
    Curran MP; Croom KF; Goa KL
    BioDrugs; 2004; 18(3):207-10. PubMed ID: 15161340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.
    Cohen MH; Williams G; Johnson JR; Duan J; Gobburu J; Rahman A; Benson K; Leighton J; Kim SK; Wood R; Rothmann M; Chen G; U KM; Staten AM; Pazdur R
    Clin Cancer Res; 2002 May; 8(5):935-42. PubMed ID: 12006504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of imatinib therapy for sickle cell anemia and chronic myeloid leukemia.
    Murphy M; Close J; Lottenberg R; Rajasekhar A
    Am J Med Sci; 2014 Mar; 347(3):254-5. PubMed ID: 24553361
    [No Abstract]   [Full Text] [Related]  

  • 17. Suboptimal responses to imatinib in chronic myelogenous leukemia: what are they and how do they affect treatment?
    Allen-Bard S
    Clin J Oncol Nurs; 2009 Oct; 13(5):537-42. PubMed ID: 19793710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
    Hardling M; Wei Y; Palmqvist L; Swolin B; Stockelberg D; Gustavsson B; Ekeland-Sjöberg K; Wadenvik H; Ricksten A
    Med Oncol; 2004; 21(4):349-58. PubMed ID: 15579919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imatinib for chronic myeloid leukaemia: a NICE mess.
    Rajaratnam G; Edwards J
    Lancet; 2001 Dec; 358(9296):1902. PubMed ID: 11741655
    [No Abstract]   [Full Text] [Related]  

  • 20. Investigator profile. Brian J. Druker, M.D. Interview by Vicki P. Glaser.
    Druker BJ
    J Hematother Stem Cell Res; 2001 Dec; 10(6):721-4. PubMed ID: 11798498
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.